Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2020 1
2021 1
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Kusunose K, Yoshida H, Tanaka A, Teragawa H, Akasaki Y, Fukumoto Y, Eguchi K, Kamiya H, Kario K, Yamada H, Sata M, Node K; PRIZE Study Investigators. Kusunose K, et al. Hypertens Res. 2022 Jan;45(1):106-115. doi: 10.1038/s41440-021-00752-9. Epub 2021 Oct 17. Hypertens Res. 2022. PMID: 34657137 Free PMC article. Clinical Trial.
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J, Tanaka A, Sato Y, Tomiyama H, Sata M, Ishizu T, Taguchi I, Kuroyanagi T, Teragawa H, Ishizaka N, Kanzaki Y, Ohishi M, Eguchi K, Higashi Y, Yamada H, Maemura K, Ako J, Bando YK, Ueda S, Inoue T, Murohara T, Node K; PRIZE Study Investigators. Oyama J, et al. Cardiovasc Diabetol. 2016 Jun 18;15:87. doi: 10.1186/s12933-016-0409-2. Cardiovasc Diabetol. 2016. PMID: 27317093 Free PMC article. Clinical Trial.
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.
Shiina K, Tomiyama H, Tanaka A, Yoshida H, Eguchi K, Kario K, Kato T, Teragawa H, Toyoda S, Ohishi M, Fukumoto Y, Takase B, Ishizu T, Node K; PRIZE Study Investigators. Shiina K, et al. Hypertens Res. 2022 Apr;45(4):602-611. doi: 10.1038/s41440-022-00857-9. Epub 2022 Feb 15. Hypertens Res. 2022. PMID: 35169280 Clinical Trial.
Effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study.
Teragawa H, Tanaka A, Fujii Y, Yoshida H, Ueda T, Nomura S, Kadokami T, Koide H, Saito M, Sano H, Bando YK, Murohara T, Node K; PRIZE Study Investigators. Teragawa H, et al. Clin Cardiol. 2023 Jun;46(6):698-706. doi: 10.1002/clc.24014. Epub 2023 Mar 29. Clin Cardiol. 2023. PMID: 36991567 Free PMC article. Clinical Trial.
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H, Sata M, Sezai A, Eguchi K, Kato T, Toyoda S, Ishibashi R, Kario K, Ishizu T, Ueda S, Maemura K, Higashi Y, Yamada H, Ohishi M, Yokote K, Murohara T, Oyama JI, Node K; PRIZE study investigators. Tanaka A, et al. PLoS Med. 2020 Apr 22;17(4):e1003095. doi: 10.1371/journal.pmed.1003095. eCollection 2020 Apr. PLoS Med. 2020. PMID: 32320401 Free PMC article. Clinical Trial.